LXRX vs MRNA · rev $21.8M vs rev $145.0M
Lexicon Pharmaceuticals Inc (LXRX) versus Moderna Inc (MRNA) — a side-by-side from cached financials, not a winner call.
Lexicon Pharmaceuticals Inc (LXRX) is a biotechnology company listed on US.
Moderna Inc (MRNA) is a biotechnology company listed on NASDAQ. It is led by Stéphane Bancel M.B.A..
Latest reported LXRX revenue for 2026-06-30 was $21.8M. Net income was -$32.8M. Revenue was up 3.3% from 2026-03-31 to 2026-06-30. LXRX currently screens at market cap $327.2M.
Latest reported MRNA revenue for 2026-06-30 was $145.0M. Net income was -$782.0M. Revenue was down 62.7% from 2026-03-31 to 2026-06-30. MRNA currently screens at market cap $24.52B.
LXRX currently screens at market cap $327.2M. MRNA currently screens at market cap $24.52B.
Not investment advice. Open the LXRX and MRNA stock pages for the full models.
Not investment advice.